|
nab-Sirolimus Clinical Trials
6 actively recruiting trials across 6 locations
Also known as: ABI-009, ABI-009, nab-rapamycin, albumin-bound rapamycin, Fyarro
Pipeline
Phase 1: 2Phase 2: 4
Top Sponsors
- Aadi Bioscience, Inc.3
- University of Oklahoma1
- Sarcoma Alliance for Research through Collaboration1
- M.D. Anderson Cancer Center1
Indications
- Cancer6
- Tumor2
- Pulmonary Neuroendocrine Tumor1
- Endometrioid Endometrial Cancer1
- Endometrioid Tumor1
Little Rock, Arkansas1 trial
Newport Beach, California1 trial
Stanford, California1 trial
Oklahoma City, Oklahoma1 trial
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
OU Health Stephenson Cancer Center
Phase 2
Houston, Texas1 trial
San Antonio, Texas1 trial
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
South Texas Accelerated Research Therapeutics, LLC
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.